Stabilized Fibronectin Domain Compositions, Methods and Uses
Summary
The European Patent Office published patent application EP4115911A1 for Janssen Biotech, Inc., covering stabilized fibronectin domain compositions and their therapeutic uses. The patent covers methods for treating neurological, cardiovascular, oncological, hematological, and ocular conditions. This publication grants public access to the patent claims under the EPC designated states.
What changed
Janssen Biotech, Inc. has been granted European Patent EP4115911A1 for stabilized fibronectin domain compositions, methods of treatment, and uses. The patent application was published March 25, 2026, with inventor Steven Jacobs, and covers pharmaceutical compositions in IPC classifications A61K 49/00, C07K 14/00, and related therapeutic applications.
This patent publication is informational and does not require immediate action from most entities. Pharmaceutical and biotechnology companies developing competing fibronectin-based therapeutics should review the claims to assess potential freedom-to-operate implications. Generic or biosimilar developers may want to evaluate design-around opportunities during product development planning.
Source document (simplified)
STABILIZED FIBRONECTIN DOMAIN COMPOSITIONS, METHODS AND USES
Publication EP4115911A1 Kind: A1 Mar 25, 2026
Applicants
Janssen Biotech, Inc.
Inventors
JACOBS, Steven
IPC Classifications
A61K 49/00 20060101AFI20221206BHEP C07K 14/00 20060101ALI20221206BHEP C40B 50/00 20060101ALI20221206BHEP C40B 40/08 20060101ALI20221206BHEP C40B 40/02 20060101ALI20221206BHEP C40B 30/04 20060101ALI20221206BHEP C07H 21/00 20060101ALI20221206BHEP C12N 15/63 20060101ALI20221206BHEP C12N 1/21 20060101ALI20221206BHEP C12N 1/19 20060101ALI20221206BHEP C12N 5/10 20060101ALI20221206BHEP A61K 38/16 20060101ALI20221206BHEP A61P 25/00 20060101ALI20221206BHEP A61K 38/22 20060101ALI20221206BHEP A61P 7/00 20060101ALI20221206BHEP A61P 27/02 20060101ALI20221206BHEP A61P 35/00 20060101ALI20221206BHEP A61P 9/00 20060101ALI20221206BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.